Dry age-related macular degeneration+1
Not yet recruitingSafety, tolerability and exploratory efficacy of PST-611 in patients with geographic atrophy secondary to age-related macular degeneration
Safety, tolerability and exploratory efficacy of PST-611 in patients with geographic atrophy secondary to age-related macular degeneration
- Disease:Dry age-related macular degenerationAge-related macular degeneration
- Substances:PST-611
France- Participants:65+ years
- Substances:PST-611
- Sponsor:PulseSight Therapeutics
